clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Parotid Diseases D010305 1 associated lipids
Achlorhydria D000126 1 associated lipids
Eye Infections D015817 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Parotid Neoplasms D010307 2 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Weese JS et al. Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseases. 2011 Vet Med Int pmid:21776346
Dhama K et al. Tuberculosis in Birds: Insights into the Mycobacterium avium Infections. 2011 Vet Med Int pmid:21776352
Rebuelto M and Loza ME Antibiotic Treatment of Dogs and Cats during Pregnancy. 2010 Vet Med Int pmid:21253497
Giguère S Treatment of Infections Caused by Rhodococcus equi. 2017 Vet. Clin. North Am. Equine Pract. pmid:28161038
Sharman MJ et al. Gastrokine mRNA expression in gastric tissue from dogs with helicobacter colonisation but without inflammatory change during treatment. 2017 Vet. Immunol. Immunopathol. pmid:28494926
Hung SW et al. Antibiotic susceptibility and prevalence of erythromycin ribosomal methylase gene, erm(B) in Streptococcus spp. 2008 Vet. J. pmid:17400007
Berghaus LJ et al. Mutant prevention concentration and mutant selection window for 10 antimicrobial agents against Rhodococcus equi. 2013 Vet. Microbiol. pmid:23915992
Hartmann FA et al. Molecular characterization of Staphylococcus intermedius carriage by healthy dogs and comparison of antimicrobial susceptibility patterns to isolates from dogs with pyoderma. 2005 Vet. Microbiol. pmid:15917140
Burton AJ et al. Efficacy of liposomal gentamicin against Rhodococcus equi in a mouse infection model and colocalization with R. equi in equine alveolar macrophages. 2015 Vet. Microbiol. pmid:25666452
Giguère S et al. In vitro synergy, pharmacodynamics, and postantibiotic effect of 11 antimicrobial agents against Rhodococcus equi. 2012 Vet. Microbiol. pmid:22704561
Sieber-Ruckstuhl NS et al. Long-term cure of disseminated Mycobacterium avium infection in a cat. 2007 Vet. Rec. pmid:17259458
Cattoli G et al. Helicobacter acinonychis eradication leading to the resolution of gastric lesions in tigers. 2000 Vet. Rec. pmid:10975334
Bruhn O et al. Antimicrobial peptides and proteins of the horse--insights into a well-armed organism. 2011 Vet. Res. pmid:21888650
Clark SE et al. Identification of a multidrug efflux pump in Flavobacterium johnsoniae. Vet. Res. pmid:19558960
Ebnöther M et al. Severe bronchiolitis in acute Mycoplasma pneumoniae infection. 2001 Virchows Arch. pmid:11787856
de Mascarel A et al. Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. 2005 Virchows Arch. pmid:15742170
Zarogoulidis P et al. Long-term respiratory follow-up of H1N1 infection. 2011 Virol. J. pmid:21702977
Morgene MF et al. HaCaT epithelial cells as an innovative novel model of rhinovirus infection and impact of clarithromycin treatment on infection kinetics. 2018 Virology pmid:30077071
Sandri A et al. Inhibition of Pseudomonas aeruginosa secreted virulence factors reduces lung inflammation in CF mice. 2018 Virulence pmid:29938577
Díte P et al. [Double blind randomized multicentre study of a seven-day eradication regime of Helicobacter pylori by omeprazole, clarithromycin and ornidazole vs. omeprazole, clarithromycin and metronidazole]. 2002 Vnitr Lek pmid:16737149
Starostin BD [Modern means of anti-Helicobacter therapy]. 2001 Voen Med Zh pmid:11764485
Vichev E et al. [Gastroduodenitis and ulcers--statistical study for 1998]. 2000 Vutr Boles pmid:11688321
Yazdanbakhsh AR et al. Reduction of non-Betalactam Antibiotics COD by Combined Coagulation and Advanced Oxidation Processes. 2016 Water Environ. Res. pmid:28661328
Nakada N et al. Removal of selected pharmaceuticals and personal care products (PPCPs) and endocrine-disrupting chemicals (EDCs) during sand filtration and ozonation at a municipal sewage treatment plant. 2007 Water Res. pmid:17632207
Abegglen C et al. The fate of selected micropollutants in a single-house MBR. 2009 Water Res. pmid:19269669
Vione D et al. Phototransformation of selected human-used macrolides in surface water: kinetics, model predictions and degradation pathways. 2009 Water Res. pmid:19249811
Wang S et al. Enhanced adsorption of ionizable antibiotics on activated carbon fiber under electrochemical assistance in continuous-flow modes. 2018 Water Res. pmid:29426033
Siemens J et al. Concentrations and mobility of human pharmaceuticals in the world's largest wastewater irrigation system, Mexico City-Mezquital Valley. 2008 Water Res. pmid:18083208
Forrez I et al. Biogenic metals for the oxidative and reductive removal of pharmaceuticals, biocides and iodinated contrast media in a polishing membrane bioreactor. 2011 Water Res. pmid:21163512
Yamashita N et al. Effects of antibacterial agents, levofloxacin and clarithromycin, on aquatic organisms. 2006 Water Sci. Technol. pmid:16862775
Sahar E et al. Comparison of two treatments for the removal of selected organic micropollutants and bulk organic matter: conventional activated sludge followed by ultrafiltration versus membrane bioreactor. 2011 Water Sci. Technol. pmid:21330721
Lin AY et al. Fate of selected pharmaceuticals and personal care products after secondary wastewater treatment processes in Taiwan. 2010 Water Sci. Technol. pmid:21076233
Ghosh GC et al. Occurrence and elimination of antibiotics at four sewage treatment plants in Japan and their effects on bacterial ammonia oxidation. 2009 Water Sci. Technol. pmid:19237773
Harada A et al. Biological effects of PPCPs on aquatic lives and evaluation of river waters affected by different wastewater treatment levels. 2008 Water Sci. Technol. pmid:19001705
Nakada N et al. Occurrence of 70 pharmaceutical and personal care products in Tone River basin in Japan. 2007 Water Sci. Technol. pmid:18075189
Sein MM et al. Oxidation of some typical wastewater contaminants (tributyltin, clarithromycin, metoprolol and diclofenac) by ozone. 2009 Water Sci. Technol. pmid:19403960
Feng X et al. [Interaction between biofilm formed by Pseudomonas aeruginosa and antibacterial agents]. 2000 Wei Sheng Wu Xue Bao pmid:12548947
Dhawan VK et al. Vancomycin-resistant enterococcal colonization in nonhospitalized HIV-infected patients. 1998 West. J. Med. pmid:9830355
Kanatani MS and Guglielmo BJ The new macrolides. Azithromycin and clarithromycin. 1994 West. J. Med. pmid:8128699
Kardas P and Muras M [A blinded comparison of palatability of 13 common pediatric antibiotic suspensions]. 2005 Wiad. Lek. pmid:15991547
Gościmski A et al. [Microflora of gastric juice in patients after eradication of Helicobacter pylori and treatment with a proton pump inhibitor]. 2002 Wiad. Lek. pmid:12043311
Kurz H and Göpfrich H [Epidemiology and morbidity of mycoplasma as causative agent for community-acquired pneumonia in hospitalized children in a Community Hospital in Vienna]. 2011 Wien Med Wochenschr pmid:20963506
Bago P et al. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. 2007 Wien. Klin. Wochenschr. pmid:17634896
Bago J et al. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial. 2002 Wien. Klin. Wochenschr. pmid:12422579
Bago J et al. Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. 2004 Wien. Klin. Wochenschr. pmid:15379146
Vcev A et al. Amoxycillin, clarithromycin and either sucralfate or pantoprazole for eradication of Helicobacter pylori in duodenal ulcer (a randomized controlled trial). 2001 Wien. Klin. Wochenschr. pmid:11802510
Li Y et al. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. 2010 Wien. Klin. Wochenschr. pmid:20628905
Nizič T et al. Solitary erythema migrans in children: comparison of treatment with clarithromycin and amoxicillin. 2012 Wien. Klin. Wochenschr. pmid:22760494
Francesco VD et al. Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal. 2011 World J Gastrointest Pathophysiol pmid:21860834
Yanai A et al. Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. 2012 World J Gastrointest Pharmacol Ther pmid:22408744
Whittemore KR and Cohen M Imaging and review of a large pre-auricular pilomatrixoma in a child. 2012 World J Radiol pmid:22761984
Grande M et al. Helicobacter pylori and gastroesophageal reflux disease. 2008 World J Surg Oncol pmid:18601740
Cavanna L et al. High grade B-cell gastric lymphoma with complete pathologic remission after eradication of Helicobacter pylori infection: report of a case and review of the literature. 2008 World J Surg Oncol pmid:18353178
Cosme A et al. Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. 2017 World J. Gastroenterol. pmid:28566898
Keshavarz AA et al. Omeprazole-based triple therapy with low-versus high-dose of clarithromycin plus amoxicillin for H pylori eradication in Iranian population. 2007 World J. Gastroenterol. pmid:17352026
Losurdo G et al. Role of concomitant therapy for eradication: A technical note. 2016 World J. Gastroenterol. pmid:27784977
Si JM et al. Quality of gastric ulcer healing evaluated by endoscopic ultrasonography. 2005 World J. Gastroenterol. pmid:15948255
Hagiwara T et al. Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection. 2007 World J. Gastroenterol. pmid:17657838
Sanches BS et al. Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil: A national survey. 2016 World J. Gastroenterol. pmid:27672279
Huang JQ et al. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. 2005 World J. Gastroenterol. pmid:15884111
Robles-Jara C et al. Is a 7-day Helicobater pylori treatment enough for eradication and inactivation of gastric inflammatory activity? 2008 World J. Gastroenterol. pmid:18473407
Koussoulas V et al. Evidence for the role of gastric mucosa at the secretion of soluble triggering receptor expressed on myeloid cells (strem-1) in peptic ulcer disease. 2007 World J. Gastroenterol. pmid:17729416
Hwang JJ et al. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. 2015 World J. Gastroenterol. pmid:25945019
Gumurdulu Y et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. 2004 World J. Gastroenterol. pmid:14991935
Guo CY et al. Clinical evaluation of four one-week triple therapy regimens in eradicating Helicobacter pylori infection. 2004 World J. Gastroenterol. pmid:14991953
Mirbagheri SA et al. Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial. 2006 World J. Gastroenterol. pmid:16937475
Lin LC et al. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials. 2016 World J. Gastroenterol. pmid:27340362
Ching SS et al. Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. 2008 World J. Gastroenterol. pmid:18609709
Trifan A et al. Pseudomembranous colitis associated with a triple therapy for Helicobacter pylori eradication. 2013 World J. Gastroenterol. pmid:24259981
Iannone A et al. New fecal test for non-invasive detection: A diagnostic accuracy study. 2018 World J. Gastroenterol. pmid:30038469
Sun QJ et al. Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai. 2010 World J. Gastroenterol. pmid:20976850
Gisbert JP "Rescue" regimens after Helicobacter pylori treatment failure. 2008 World J. Gastroenterol. pmid:18803350
Chuah SK et al. A new look at anti-Helicobacter pylori therapy. 2011 World J. Gastroenterol. pmid:22046084
Matta AJ et al. Punctual mutations in gene of clarithromycin-resistant in Colombian populations. 2018 World J. Gastroenterol. pmid:29662291
Lee HJ et al. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. 2015 World J. Gastroenterol. pmid:25574111
Brennan DE et al. Can bacterial virulence factors predict antibiotic resistant infection? 2018 World J. Gastroenterol. pmid:29531461
Buzás GM and Józan J First-line eradication of H pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2004. 2006 World J. Gastroenterol. pmid:16981260
Babic Z et al. Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection. 2005 World J. Gastroenterol. pmid:15884110
Ji F et al. Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylori: a randomized, controlled trial. 2006 World J. Gastroenterol. pmid:16586550
Zhou Q et al. Drug utilization of clarithromycin for gastrointestinal disease treatment. 2008 World J. Gastroenterol. pmid:18932287
Sereni G et al. Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection. 2012 World J. Gastroenterol. pmid:22969227
Isomoto H et al. Sofalcone, a mucoprotective agent, increases the cure rate of Helicobacter pylori infection when combined with rabeprazole, amoxicillin and clarithromycin. 2005 World J. Gastroenterol. pmid:15786539
Wang HH et al. One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy. 2005 World J. Gastroenterol. pmid:15786549
Aydemir S et al. Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. 2005 World J. Gastroenterol. pmid:15682477
O'Morain C Role of Helicobacter pylori in functional dyspepsia. 2006 World J. Gastroenterol. pmid:16718752
Sugimoto M and Furuta T Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. 2014 World J. Gastroenterol. pmid:24914361
Heo J and Jeon SW Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. 2014 World J. Gastroenterol. pmid:24914324
Sun WH et al. Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. 2005 World J. Gastroenterol. pmid:15832421
Wu IT et al. Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan. 2015 World J. Gastroenterol. pmid:26457027
Bustamante-Rengifo JA et al. Effect of treatment failure on the CagA EPIYA motif in strains from Colombian subjects. 2017 World J. Gastroenterol. pmid:28373764
Chen KY et al. Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial. 2015 World J. Gastroenterol. pmid:26420970
Hwang JJ et al. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. 2015 World J. Gastroenterol. pmid:26401089
Sakurai K et al. Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. 2017 World J. Gastroenterol. pmid:28216974
Onyekwere CA et al. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study. 2014 World J. Gastroenterol. pmid:24707145
Wu JY et al. Detection of genotypic clarithromycin-resistant Helicobacter pylori by string tests. 2014 World J. Gastroenterol. pmid:24695835
Gao XZ et al. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. 2010 World J. Gastroenterol. pmid:20818821
Mabe K et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer? 2009 World J. Gastroenterol. pmid:19750572
Garza-González E et al. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. 2014 World J. Gastroenterol. pmid:24587620
Riquelme A et al. Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile. 2007 World J. Gastroenterol. pmid:17589948
Ersoy O et al. H pylori infection in patients with Behcet's disease. 2007 World J. Gastroenterol. pmid:17589951